The high iatrogenic multiple pregnancy rate associated with intrauterine insemination (IUI) in hyperstimulated cycles is becoming less acceptable. Therefore we investigated data from an earlier prospective trial with regard to the specific question of whether the application of mild hyperstimulation in IUI cycles could be an alternative strategy for obtaining acceptable pregnancy rates while preventing a high multiple pregnancy rate, compared with natural cycles for IUI. METHODS: Pregnancy outcome of 310 natural and 334 mildly hyperstimulated cycles for IUI in 171 couples with unexplained or mild male factor subfertility was analysed on a patient level with random coefficient models. RESULTS: Pregnancy rates were similar: 35 and 39.8% per couple in the natural and mildly hyperstimulated cycles respectively (P = 0.60). Multiple pregnancies, all twin pregnancies, were conceived significantly more frequently in the mild hyperstimulation group (27% of the pregnancies) than in the natural cycle group (4% of the pregnancies) (P = 0.01). All multiple pregnancies in the hyperstimulation group were conceived in multifollicular cycles. Multifollicular development was strongly associated with the application of mild hyperstimulation only (odds ratio 21.14, 95% confidence interval 8.15-54.79). CONCLUSION: The application of a mild hyperstimulation protocol as an alternative to a standard hyperstimulation protocol for IUI does not result in higher pregnancy rates than IUI in the natural cycle, while at the same time multiple pregnancies cannot be avoided. Therefore, there is no place for the use of gonadotrophins in IUI treatment.
Introduction
Intrauterine insemination (IUI) is used frequently in the treatment of couples with subfertility where there is still at least one patent tube. The application of ovarian stimulation is advocated, even if the woman has ovulatory cycles, to improve the pregnancy rates with IUI (Hughes, 1997) .
The application of ovarian stimulation, however, has two main complications: the increased chances of a multiple pregnancy and of the occurrence of ovarian hyperstimulation syndrome. For a long time the increased chance of conceiving in hyperstimulated IUI cycles was considered to be the justification for applying hyperstimulation, even in large daily dosages of 150-225 IU gonadotrophins. However, major concerns over the increased incidence of multiple pregnancies are being raised (Bhattacharya, 2000; Hale, 2003; Stewart, 2003; Fauser et al., 2005; Ombelet et al., 2005) . The ESHRE Capri Workshop Group that convened in 1999 even went as far as stating that superovulation in combination with IUI is not a very safe technique and its benefits may not outweigh the associated hazards of multiple gestation pregnancy (ESHRE Capri Workshop Group, 2000) . On the other hand, IUI in hyperstimulated cycles is considered more cost-effective than IVF (Peterson et al., 1996) and may therefore be more easily affordable for infertile couples. For the purpose of retaining an increased chance of pregnancy after treatment with an acceptable multiple pregnancy rate, milder stimulation schemes for IUI treatment have been analysed.
Only a few studies have been conducted on this issue. In a randomized trial that analysed three different low-intensity stimulation protocols for their efficacy, total amounts of 300-600 IU recombinant FSH (recFSH) were administered in women with unexplained subfertility prior to IUI. This resulted in an overall pregnancy rate of only 2.3% per ovulatory cycle, with no multiple pregnancies occurring (Hughes et al., 1998) . In a recent retrospective analysis of IUI in cycles stimulated with daily dosages from 50 to 75 IU recFSH, an overall pregnancy rate of 10% per started cycle was reported, 8% of all pregnancies being multiple pregnancies, including one triplet (Papageorgiou et al., 2004) . These studies show how difficult it is to maintain the balance between an acceptable pregnancy rate and minimal risk of multiple pregnancy.
With only a small number of studies on this issue available, we decided to perform additional analyses of the data we had previously collected on the efficacy of IUI in natural and mildly hyperstimulated cycles in couples with unexplained and mild male subfertility in terms of achieving clinical pregnancy and multiple pregnancy (Goverde et al., 2000) . In that trial we did not find a significant difference in pregnancy and delivery rates after IUI in the mildly hyperstimulated cycle versus the natural cycle. We decided to re-evaluate the original data with the aim of analysing which factors are associated with the outcomes of these treatments and to find an explanation for our earlier findings.
Materials and methods
This study was part of a prospective randomized study on the costeffectiveness of treatment with IUI or IVF (Goverde et al., 2000) . For this report, we focus on IUI data only. A total of 171 couples who underwent IUI were studied for the effects of mild hyperstimulation versus no stimulation cycles on ongoing and multiple pregnancy rates after IUI.
Couples had suffered from unexplained subfertility for at least 3 years or mild to moderate male subfertility for at least 1 year. They were diagnosed as having unexplained subfertility if no abnormality was found during an extensive investigation of infertility, including a basal body-temperature chart, a late luteal-phase endometrial biopsy, a postcoital test, a hysterosalpingogram, a diagnostic laparoscopy, and at least two semen analyses. Male subfertility was diagnosed if at least three out of five semen analyses showed a total motile sperm count of fewer than 20 ×10 6 progressively motile spermatozoa in the ejaculate and if the remainder of the infertility investigation revealed no additional abnormalities. In both groups of patients, semen processing by gradient centrifugation yielded a minimum of 1 ×10 6 progressively motile spermatozoa at least once. Couples were excluded if there were cycle disorders, untreated endometriosis (American Society of Reproductive Medicine criteria grade 2-4), or bilateral occluded tubes, or if a semen sample yielded fewer than 1 ×10 6 progressively motile spermatozoa after processing by gradient centrifugation, if more than 20% of spermatozoa carried antibodies as tested with an immunobead test after processing, or if more than 50% of spermatozoa had no acrosome. Couples with a viable pregnancy at 12 weeks of gestation were excluded from further treatment within the study, irrespective of the outcome of pregnancy (Goverde et al., 2000) . For the purpose of this study, we only analysed the cycles in which IUI was performed in either a natural or mildly hyperstimulated cycle.
For IUI in the natural cycle, women underwent a basal transvaginal ultrasound assessment at the beginning of their menstrual period, and on the 10th day of the cycle for research purposes. Patients tested their urine samples twice daily (second morning void and between 18.00 h and 19.00 h) with a urinary semiquantitative monoclonal antibodybased kit with a detection level of 40 IU (OvuQuick; Quidel, San Diego, CA, USA) starting on an individually calculated cycle day (McIntosh et al., 1980) for the occurrence of an endogenous LH surge. As soon as they had detected the LH surge, patients contacted the clinic and ultrasonography was performed to assess follicular development. A single IUI was done 20-30 h after the detection of the LH peak. A maximum of 0.5 ml suspension of processed spermatozoa was introduced into the uterine cavity with a catheter of 10 cm length (International Medical, Zutphen, The Netherlands). Patients were tested for pregnancy if menstruation had not started on the 17th day after insemination.
The stimulation protocol for the IUI treatment in mildly hyperstimulated cycles stipulated a low dose of FSH in order to limit the number of dominant follicles to three or fewer, with the goal of optimizing the pregnancy rate while preventing a high multiple pregnancy rate. Multifollicular growth was defined as the growth of more than one follicle with a diameter of ≥14 mm on the day of HCG administration. Baseline pelvic ultrasonography was done at cycle day 3 to exclude ovarian cysts larger than 20 mm. When this point had been reached, patients injected themselves intramuscularly with one ampoule (75 IU) FSH (Metrodin; Ares Serono, Geneva, Switzerland) daily until transvaginal ultrasonography showed at least one follicle with a diameter of 18 mm. Patients tested their urine twice daily (morning and evening void) for the occurrence of an LH surge. In the event of such a surge, 10 000 IU HCG (Profasi; Ares Serono) was given as soon as possible, and a single IUI was done 20-30 h after the detection of the surge. When no LH surge was detected in the presence of at least one follicle with a diameter of 18 mm or more, 10 000 IU of HCG was given intramuscularly, and a single IUI was done 40-42 h later. The administration of HCG was withheld and IUI was not performed when more than three follicles ≥18 mm or more than six follicles ≥14 mm were present. The daily dose of FSH was increased by 0.5 ampoule in every subsequent cycle when the dose of the previous cycle had resulted in monofollicular growth. Patients were tested for pregnancy if menstruation had not started on the 17th day after insemination.
Pregnancy was defined as ongoing pregnancy with at least one fetal heartbeat at 12 weeks of gestation, and multiple pregnancy was defined as more than one fetal heartbeat at 12 weeks of gestation.
On the third day of the menstrual period, a blood sample was drawn to measure the serum levels of FSH and estradiol (E 2 ), irrespective of whether hyperstimulation was applied. On the day of the detection of an LH peak, or HCG administration, a blood sample was drawn to assess the serum level of progesterone and E 2 . FSH, E 2 and progesterone were measured with commercially available competitive immunoassays (Amerlite; Amersham, UK). For FSH, the inter-assay coefficient of variation (CV) was 9% at 3 IU/l and 5% at 35 IU/l, and the intra-assay CV was 9% at 5 IU/l, 8% at 15 IU/l and 6% at 40 IU/l. The lower limit of detection was 0.5 IU/l. For E 2 , the inter-assay CV was 11% at 250 pmol/l and 8% at 8000 pmol/l, and the intra-assay CV was 13% at 250 pmol/l, 9% at 1100 pmol/l and 9% at 5000 pmol/l. The lower limit of detection was 90 pmol/l (conversion factor to the metric system, 0.2724). For progesterone, the inter-assay CV was 16.9% at 2.66 nmol/l, 6.6% at 33.1 nmol/l and 7.1% at 71.7 nmol/l, and the intra-assay CV was 11.1% at 3.34 nmol/l, 7.0% at 34.1 nmol/l and 7.3% at 70.6 nmol/l (conversion factor to the metric system, 0.3145).
To prepare semen, fresh and liquefied ejaculates were processed by centrifugation over a 40/80 density gradient at 750 g for 15 min. The pellet was resuspended in 2 ml Earl's+ medium. The isolated spermatozoa were spun down at 300 g for 7 min, and this pellet was resuspended in 2 ml of culture medium and stored in 5% carbon dioxide in air at room temperature. Just before insemination, the spermatozoa were spun down at 200 g for 7 min. This final pellet, irrespective of the number of concentrated spermatozoa, was resuspended in 0.2-0.4 ml culture medium.
Statistical analysis
Univariate comparisons were carried out using the t-test and χ 2 test. Log-transformation of serum progesterone and E 2 concentrations was performed because of skewed distribution. The probability of multifollicular development was analysed with woman's age, basal FSH concentration, treatment, indication and total FSH dosage as explanatory variables. The probability of achieving ongoing pregnancy was analysed using multivariate logistic regression models with woman's age, treatment, indication, total motile sperm count after processing on the day of insemination and number of follicles ≥14 mm on the day of LH peak or HCG administration as explanatory variables. Age and total motile sperm count were entered into the regression models as continuous variables, whereas treatment and indication were entered as binary parameters. The number of follicles ≥14 mm on the day of the LH peak or HCG administration was entered as a binary value as well, reflecting either monofollicular or multifollicular development in both spontaneous and mildly hyperstimulated cycles.
The patient was the unit of analysis. We used random coefficient models to carry out the regression analyses. As each patient received one or more treatment cycles, it cannot be assumed that all observations are independent. The random coefficient models incorporate 'clustering' of observations (in this case, within patients), allow modelling of these dependencies and provide information on inter-patient variability (Longford, 1993; Goldstein, 1995) . We considered P-values less than 0.05 to be statistically significant. All statistical analyses were carried out using Stata 8.0.
Results
As we had shown earlier (Goverde et al., 2000) , patient characteristics in both groups after randomization showed no significant differences (Table I) . Table II shows the specific cycle parameters. The cycles in which ovarian stimulation was applied had higher numbers of follicles ≥14 mm and higher concentrations of E 2 and progesterone on the day of HCG administration compared with natural cycles (P < 0.001, P < 0.001 and P = 0.003 respectively). In both treatment groups the parameters for the female patients with unexplained subfertility compared with mild male subfertility were similar. For this reason, in all subsequent analyses both indications were analysed together and, where appropriate, the total motile sperm count was used as a separate, continuous variable.
Multifollicular development was seen in 262 of the total of 644 cycles [in 23 of 310 natural cycles (8%) and in 239 of 334 stimulated cycles (72%)]. Multifollicular development was associated with the application of mild hyperstimulation only, and was not associated with woman's age, basal FSH level, diagnosis or, in the case of hyperstimulation, with the total amount of FSH administered (Table III) .
Pregnancies occurred from the first until the sixth treatment cycle, 32% of all pregnancies occurring in the first cycle. There were 28 ongoing pregnancies in the IUI alone group (9.0% per cycle, 35% per couple that started treatment); for 25 of these a live baby was delivered (delivery rate 8.1% per cycle, 31.3% per couple). Table II . Cycle characteristics: basal FSH concentration on cycle day 3, number of follicles ≥14 mm and oestradiol and progesterone concentrations on the day of HCG administration and inseminated number of total progressively motile spermatozoa (VCM) for each diagnostic and treatment group a P < 0.001 for IUI alone versus IUI with hyperstimulation for unexplained and male subfertility. b P < 0.001 for IUI alone versus IUI with hyperstimulation for unexplained subfertility, and P = 0.004 for IUI alone versus IUI with hyperstimulation for male subfertility. c P = 0.007 for IUI alone versus IUI with hyperstimulation for male subfertility, and P = 0.005 for IUI alone versus IUI with hyperstimulation for unexplained subfertility. d P = 0.03 for IUI alone versus IUI with hyperstimulation for male subfertility.
Basal FSH (IU/L) Follicles
Idiopathic subfertility IUI alone 1st cycle 6.9 ± 0.7 1.0 ± 0.05 586 ± 49 3.2 ± 0.2 14.1 ± 1.6 All cycles 6.5 ± 0.2 1.0 ± 0.03 623 ± 32 3.7 ± 0.6 12.3 ± 0.7 IUI with hyperstimulation 1st cycle 7.1 ± 0.5 1.9 ± 0.11 1386 ± 175 2.3 ± 0.2 11.4 ± 1.1 All cycles 7.2 ± 0.3 2.3 ± 0.09 1710 ± 132 2.2 ± 0.1 11.4 ± 0.7 Male subfertility IUI alone 1st cycle 6.0 ± 0.4 1.1 ± 0.4 519 ± 53 2.9 ± 0.3 1.7 ± 0.3 All cycles 6.0 ± 0.2 1.1 ± 0.0 570 ± 36 3.0 ± 0.1 1.6 ± 0.2 IUI with hyperstimulation 1st cycle 6.1 ± 0.4 2.0 ± 1.1 1276 ± 232 1.9 ± 0.2 4.8 ± 1.4 All cycles 6.5 ± 0.3 2.6 ± 0.1 1641 ± 140 2.2 ± 0.2 4.2 ± 0.7
One of the ongoing pregnancies was a monozygotic twin pregnancy, complicated by immature rupture of membranes, after which the twins were stillborn. In the group treated with IUI after hyperstimulation, there were 33 pregnancies (9.9% per cycle, 39.8% per couple), 31 of which resulted in delivery (delivery rate 9.3% per cycle, 37.3% per couple). Of the pregnancies occurring in the group treated with IUI in hyperstimulated cycles, nine (27% of all pregnancies in this group) were multiple pregnancies, all resulting from multifollicular cycles (Table IV) . The overall pregnancy rates in both groups were not statistically significantly different (P = 0.6), but the multiple pregnancy rate was significantly higher in IUI cycles in which mild hyperstimulation was applied (P = 0.01). None of the examined explanatory variables, e.g. woman's age, treatment, indication, total motile sperm count after processing and number of follicles ≥14 mm on the day of the LH peak or HCG administration, was associated with achieving pregnancy.
Discussion
In this study, using data from a prospective and randomized patient cohort, we evaluated which factors were associated with the outcomes of treatment in IUI in mildly hyperstimulated or natural cycles. We had already concluded from our earlier report (Goverde et al., 2000) that the application of a mild hyperstimulation protocol did not increase the overall pregnancy rate per couple, whereas the multiple pregnancy rate was significantly higher if hyperstimulation was applied. The additional analyses we report here show that the number of follicles at the time of HCG administration or the endogenous LH surge was higher in hyperstimulated cycles and that no factor other than the application of the mild hyperstimulation protocol was associated with multifollicular development. Thus importantly, although the number of pre-ovulatory follicles is increased in cycles in which a mild hyperstimulation protocol is applied, the overall chance of conceiving does not increase, while at the same time there is an additional risk of multiple pregnancy compared with no stimulation at all.
Only one other study has compared the natural cycle with a mild hyperstimulation protocol for IUI in cases of male subfertility (Cohlen et al., 1998) , and there are a few other studies that have specifically addressed the application of mild hyperstimulation in IUI cycles in order to maintain an acceptable pregnancy rate while preventing multiple pregnancies (Balasch et al., 1994; Hughes et al., 1998; Sengoku et al., 1999; Ragni et al., 2004) . These studies differed from ours in a number of ways: (i) the timing of when to start the mild hyperstimulation; (ii) the specific dosage schedule, (iii) although all report on ovarian response and pregnancy and multiple pregnancy rates, there were significant differences in design and analysis, between these reports and ours. For instance, the study performed by Cohlen et al. (1998) had a crossover design, which makes a comparison at the level of the couple difficult. The studies by Sengoku et al. (1999) and Ragni et al. (2004) involved first treatment cycles only. Finally, the studies by Balasch et al. (1994) , Hughes et al. (1998) and ours are of parallel design but the number of cycles included differed, with a maximum of two in the studies by Balasch et al. (1994) and Hughes et al. (1998) and a maximum of six treatment cycles in our study.
In the study by Cohlen et al. (1998) only male subfertility couples were included, to undergo either natural cycle IUI or IUI in the mildly hyperstimulated cycle in a crossover design with a maximum of six treatment cycles. Their mild hyperstimulation protocol was similar to ours, although our criteria to cancel IUI at either >3 follicles ≥16 mm or >6 follicles ≥14 mm were stricter than theirs (≥4 follicles ≥18 mm or E 2 concentration >1635 pmol/l). No significant differences in pregnancy rates after IUI in the natural cycle (8.1% per started cycle) and in the mildly hyperstimulated cycle (13.2%; odds ratio 1.71, 95% confidence interval 0.82-3.57) were found. Although it is impossible to compare their results with ours on the patient level, the pregnancy rates they obtained seem similar to ours. An interesting finding, however, was the tendency for higher pregnancy rates in hyperstimulated IUI cycles in which the total motile sperm counts were approaching normospermia. We were not able to confirm this in our study. The mild hyperstimulation protocol in the study of Balasch et al. (1994) stipulated starting daily dosages of 75 IU FSH from cycle day 7 onwards, which resulted in multiple follicular growth in only 8% of the cycles, a pregnancy rate of 13% per cycle and no multiple pregnancies at all. However, one may question the rationale of applying gonadotrophins if 92% of the stimulated cycles show an ovarian response comparable to a natural cycle. In another randomized trial comparing three different low-dose stimulation protocols, multifollicular development was seen in 6-30% of the cycles depending on the total amount of FSH administered. Disappointingly, the pregnancy rate was only 1.8% per started cycle, which led to the conclusion that these protocols could not be advocated as a possible alternative for standard stimulation protocols (Hughes et al., 1998) . In yet another small randomized trial that compared a conventional stimulation protocol with a low-dose step-up protocol comparable to ours, overall and multiple pregnancy rates were almost similar (Sengoku et al., 1999) . The authors obtained a slightly higher pregnancy rate than we did (14.3% per cycle versus 9.9% per cycle in our study), although their low-dose step-up protocol resulted in monofollicular development more often than ours (49% of the cycles versus 28% monofollicular development in stimulated cycles in our study). A possible explanation for this disparity in pregnancy rates may be that in their study only the first cycle was taken into account, whereas we included up to six cycles in the analysis.
In the most recent trial, two mild hyperstimulation protocols were evaluated during the concomitant use of a GnRH antagonist in a total of 63 first treatment cycles (Ragni et al., 2004) . It was shown that daily administration of a low dose of recFSH was more effective than administration of low-dose recFSH on alternating days in terms of multifollicular development (67.7 and 37.3% of the cycles with >1 follicle ≥11 mm respectively) and pregnancy rate (34.4 and 5.9% respectively), and no multiple pregnancies were conceived. The pregnancy rate in the group with daily low-dose hyperstimulation is much higher compared with the pregnancy rates obtained in all other studies with a low-dose hyperstimulation protocol. The most striking difference from the other studies is the use of a GnRH antagonist, but whether this may have been the critical factor still needs to be elucidated. As mentioned previously, only the first cycle was analysed here, whereas we included data from up to six cycles.
From a large retrospective analysis of 3219 IUI cycles, it was concluded that it is indeed possible to lessen the multiple pregnancy risk with minimal stimulation. Gonadotrophins were administered at a starting dose of 50-75 IU daily for 4 days and adjusted according to ultrasound evaluation, which resulted in a pregnancy rate of 10% per started cycle and a multiple pregnancy rate of 1% per cycle, which was 8% of all pregnancies (Papageorgiou et al., 2004) . The overall pregnancy rate in this study was remarkably similar to the pregnancy rates we obtained in both our mild hyperstimulation and natural IUI cycles.
In assessing whether or not to apply ovarian stimulation in IUI, there are three considerations. Firstly, standard gonadotrophin stimulation with daily dosages of 150 IU or more yields high pregnancy rates by increasing the number of pre-ovulatory follicles (Tomlinson et al., 1996; Hughes, 1997; Nuojua-Huttunnen et al., 1999; Dickey et al., 2001; Duran et al., 2002; Ibérico et al., 2004) , but at the cost of a high multiple pregnancy rate (Nuojua-Huttunnen et al., 1999; Pasqualotto et al., 1999; ESHRE Capri Workshop Group, 2000; Gleicher et al., 2000; Khalil et al., 2001) , the risk of ovarian hyperstimulation syndrome, and the high costs of medication. Because of these drawbacks, this option is unacceptable. Secondly, the studies on mild hyperstimulation protocols for IUI show how difficult it is to maintain the balance between an acceptable pregnancy rate and minimizing, but not completely avoiding, the risk of multiple pregnancy. Additionally, the risk of ovarian hyperstimulation syndrome and the cost of medication also have to be taken into account in addressing the question of whether mild hyperstimulation might be more favourable for couples undergoing IUI treatment for their unexplained or mild male subfertility, compared with no stimulation at all. We have shown already that the cost-effectiveness ratio for IUI in natural cycles is more favourable than that for IUI in mildly hyperstimulated cycles in both male and idiopathic subfertility, even when costs of multiple pregnancies are not taken into account (Goverde et al., 2000) . We have not studied the cost-effectiveness of IUI in natural versus IUI in mildly hyperstimulated cycles in relation to the severity of the semen defect. Studies on which treatment option should be offered as a first choice, considering efficacy and cost-effectiveness in relation to sperm parameters, should be performed-preferably using data on the semen sample obtained during the fertility investigation. These studies are lacking at the moment (van Weert et al., 2004) but are on their way. Finally, IUI in the natural cycle has proven to be as effective a treatment as IUI with mild hyperstimulation protocols, with no additional iatrogenic risk of multiple pregnancy.
In conclusion, the use of gonadotrophins in a mild hyperstimulation protocol for IUI does not result in higher pregnancy rates than IUI in the natural cycle, and at the same time multiple pregnancies cannot be avoided. Therefore, there is no place for the use of gonadotrophins in IUI treatment.
